BC Platforms (BCP), a global leader in healthcare data management and analytics, today announces a strategic partnership with NTT in Japan to accelerate data-driven medicine. This collaboration will introduce a national medical data distribution platform to integrate, curate, and harmonize Japanese healthcare data. The primary goal of the partnership is to provide a positive impact on patients through personalized medicine. Financial details are not disclosed.
The key benefit is that this partnership with NTT ensures BC Platforms technology solutions (Trusted Research Environment Platform) usage at scale in Japan. It makes BCP a leading combined data and technology company in Asia.
The collaboration brings together four organizations based in Tokyo: Nippon Telegraph and Telephone Corporation (NTT); NTT Life Sciences Corporation; New Medical Real World Data Research Organization Inc. (PRiME-R); and Bio-Xcelerator, Inc. With approximately 338,000 employees worldwide, NTT is one of the world’s largest technology companies.
The partnership with NTT gives BC Platforms a strong foothold in the Japanese market. Our goal is to build the world’s largest health data network. With NTT’s innovative capabilities, we can offer pharmaceutical, biotech and medtech companies unique and seamless access to real-world data, making it easier, faster and more complete than any other alternative.
Tero Silvola, CEO, BC Platforms
The partnership aims to create a system to enable better utilization of data through collaboration with government agencies and companies. The goal is to implement services by NTT Life Sciences and PRiME-R built on BCP’s technology.
“We aim to harness data-driven insights to advance precision medicine and enhance patient outcomes, reinforcing NTT Life Science’s commitment to transformative healthcare solutions.
Koji Korekawa, President and CEO of NTT Life Sciences and President of PRiME-R
The partnership addresses Japan’s rising medical costs and need for innovation in healthcare. By making real-world data more accessible, the platform will support developing new therapies in a data-driven, evidence-based approach.
We are delighted to be an integral player in this unprecedented partnership to advance the future of medicine in Japan, and beyond.
Nino da Silva, MD Asia, BC Platforms